Dermatol. praxi. 2024;18(4):172-176 | DOI: 10.36290/der.2024.034

Side effects of methotrexate at low doses

MUDr. Alena Stumpfová
Kožní oddělení, Krajská zdravotní, a. s., Masarykova nemocnice v Ústí nad Labem, o. z.

Methotrexate (MTX) is a folic acid antagonist with a broad spectrum of use in the treatment of (haemato)oncological, dermatological, rheumatological and other autoimmune diseases (E, B). Since 1971, it has been approved in the treatment of severe and generalized forms of psoriasis, and has also found its utilization in the treatment of other chronic skin diseases. Although it is a very effective drug and, given its variability of use, unique, its numerous adverse effects (AEs) are also known. Due to the lack of specific markers of MTX toxicity, their occurrence cannot be predicted. However, it is safe and well tolerated if certain dosing and treatment monitoring rules are followed. This article focuses on the description of the most common and serious AEs in low-dose administration, specifies their pitfalls and describes preventive and therapeutic arrangements so that MTX can be used by physicians and patients without concern.

Keywords: methotrexate, low dose, adverse effects, side effects.

Accepted: November 6, 2024; Published: November 22, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stumpfová A. Side effects of methotrexate at low doses. Dermatol. praxi. 2024;18(4):172-176. doi: 10.36290/der.2024.034.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 22.11.2025

    References

    1. Balk RA. Methotrexate-induced lung injury. Online. UpToDate. 2024. Available from: z: https://www.uptodate.com/contents/methotrexate-induced-lung-injury?search=mehtotrexate%20induced%20lung & source=search_result & selectedTitle=1%7E150 & usage_type=default & display_rank=1.
    2. Shah R, Nwannunu CE, Limmer Al. Brief Update on Dermatologic Uses of Methotrexate. STL. 2019;24:6.
    3. Scheinfeld N. Three cases of toxic skin eruptions due to methotrexate and a compilation of methotrexate induced skin eruptions. Online. Dermatology online Journal. 2006;12:7. Available from: https://doi.org/doi.org/10.5070/D30nq2c0bx. Go to original source...
    4. Řiháček M, Pilátová K, Štěrba J, et al. New Findings in Methotrexate Pharmacology - Diagnostic Possibilities and Impact on Clinical Care. Online. Klinicka onkologie. 2015;28(3):163-170. Available from: https://doi.org/10.14735/amko2015163. Go to original source... Go to PubMed...
    5. Řiháček M, Řiháček In, Zdražilová-Dubská L, et al. 70 let methotrexátu v léčbě autoimunitních a nádorových onemocnění. Čes-slov Pediatr. 2014;69(3):161-167.
    6. Ezhilarasan D. Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanism. Online. Toxicology. 2021;458:1-8. Available from: https://doi.org./10.1016/j.tox.2021.152840. Go to original source... Go to PubMed...
    7. Nežádoucí účinky léčiv. Informační zpravodaj, Státní úřad pro kontrolu léčiv. Farmakovigilance. 2023;16(3):1-11.
    8. Kremer JM. Use of methotrexate in the treatment of rheumatoid arthritis. Online. UpToDate. 2024;-18. Available from: z: https://www.uptodate.com/contents/use-of-methotrexate-in-the-treatment-of-rheumatoid-arthritis.
    9. Kremer JM. Major adverse effects of low-dose methotrexate. Online. UpToDate. 2024;1-10. Available from: https://www.uptodate.com/contents/major-adverse-effects-of-low-dose-methotrexate?search=major%20adverse%20efect%20of%20low%20dose%20methotrexate & source=search_result & selectedTitle=1%7E150 & usage_type=default & display_rank=1.
    10. Lacasce AS. Therapeutic use and toxicity of high-dose methotrexate. Online. UpToDate. 2024;1-10. Available from: https://www.uptodate.com/contents/therapeutic-use-and-toxicity-of-high-dose-methotrexate.
    11. Souhrn údajů o přípravku. Příloha k sp. zn. sukls239559/2009: Trexan 2,5 mg tablety.
    12. Otero ME, Van Den Reek JM, Seyger MM, et al. Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE. Online. British Journal of Dermatology. 2017;177(2):497-504. Available from: https://doi.org/10.1111/bjd.15305. Go to original source... Go to PubMed...
    13. Mrážik P, Vargová V. Gastrointestinálně nežiaduce účinky metotrexátu v liečbe pacientov s juvenilnou idiopatickou artritídou - vieme ich správne hodnotiť? Čes-slov Pediat. 2015;70(4):215-219.
    14. Liu H, Liu F Zhang M, et al. Combined acute interstitial pneumonitis and pancytopenia induced by low-dose methotrexate in a hemodialysis patient treated for bullous pemphigoid. Online. Anais Brasileiros de Dermatologia. 2015;90(3):suppl 1, s. 43-45. Available from: https://doi.org/10.1590/abd1806-4841.20153692. Go to original source... Go to PubMed...
    15. Svobodová R. Současné postavení metotrexátu v léčbě revmatoidní artritidy. Prakt. lékáren. 2014;10(6):206-209.
    16. West J, Ogston S, Foester J, et al. Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials. Online. PLOS ONE. 2016;11:5. Available from: https://doi.org/10.1371/journal.pone.0153740. Go to original source... Go to PubMed...
    17. Singh SK, Singnarpi SN. Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial. Online. Indian Journal of Dermatology, Venereology and Leprology. 2021;87:214-222. Available from: https://doi.org/10.25259/IJDVL_613_19. Go to original source... Go to PubMed...
    18. Bhat T, Coughlin CC. Mood changes with methotrexate therapy for dermatologic disease. Online. Pediatric Dermatology. 2018;35(2):253-254.doi: 10.1111/pde.13406. Epub 2018 Jan 9. PMID: 29315793. Go to original source... Go to PubMed...
    19. Kamangar F, Berger TG, Fazel N. Methotrexate Toxicity Induced by Ciprofloxacin Leading to Psoriatic Plaque Ulceration: A Case Report. Cutis. 2013;92:148-150.
    20. Zgažarová L. Ulcerace rtu jako nežádoucí účinek terapie methotrexátem. Dermatol. praxi. 2020;14(1):36-38. Go to original source...
    21. Giraldi CN, Lynch DT. EBV Positive Mucocutaneous Ulcer. Online. In: National Library of Medicine. Stat Pearls; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539738/.
    22. Famenini S. Partial Reversal of Androgenetic Alopecia With Methotrexate Therapy for Psoriasis. Cutis. 2013;92:127-128.
    23. Singh SK, Singnarpi SR. Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial. Online. Indian Journal of Dermatology, Venereology and Leprology. 2021;87:214-222. Available from: https://doi.org/10.25259/IJDVL_613_19.Další literatura u autora a na www.dermatologiepropraxi.cz Go to original source...
    24. Shetty A, Cho W, Alazawi W, et al. Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease. Online. The American Journal of the Medical Sciences. 2017;354(2):172-181. Available from: https://doi.org/10.1016/j.amjms.2017. 03. 014. Go to original source...
    25. Knöpfel N, Noguera-Morel L, Hernandéz-Martin A, et al. Methotrexate for severe nummular eczema in children: Efficacy and tolerability in a retrospectiv study of 28 patientse. Online. Pediatric Dermatology. 2018;35(5):1-5. Available from: https://doi.org/10.1111/pde13568. Go to original source...
    26. Mori S, Hidaka M, Kawakita T, et al. Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases. Online. PLOS ONE. 2016;11(4). Available from: https://doi.org/10.1371/journal.pone.0154744. Go to original source... Go to PubMed...
    27. Skřičková J. Pneumocystová pneumonie. Klin Farmakol Farm. 2005;19:106-110.
    28. Ibrahim A, Ahmed M, Conway R, et al. Risk of Infection with Methotrexate Therapy in Inflammatory Diseases: A Systematic Review and Meta-Analysis. Online. Journal of Clinical Medicine. 2019;8:1. Available from: https://doi.org/10.3390/jcm8010015. Go to original source... Go to PubMed...
    29. Wang SH, Tang SE, LI YH, et al. Pneumocystis jirovecii pneumonia induced by low-dose methotrexate in a patient with chronic urticaria. Online. Anais Brasileiros de Dermatologia. 2017;92(3):401-403. Available from: https://doi.org/10.1590/abd1806-4841.20175392. Go to original source... Go to PubMed...
    30. Theodosiou G, Svensson Å. Methotrexate-associated Sexual Dysfunction: Two Case Reports. Online. Acta Dermato Venereologica. 2017;97(9):1132-1133. Available from: https://doi.org/10.2340/00015555-2714. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.